Sab Biotherapeutics, Inc. · NASDAQ:SABS

Sab Biotherapeutics — Investor Presentation (May 2023)

44 slides from Sab Biotherapeutics's investor presentation, May 12, 2023

  1. Slide 1: Advancing a Powerful New Class of Therapeutic Immunoglobulin (hIgG)

    4. » / BIOTHERAPEUTICS ADVANCING A POWERFUL NEW CLASS OF THERAPEUTIC IMMUNOGLOBULIN (hlgG) May 2023

  2. Slide 2: SAB-176 & SAB-185 Designations & Announcements

    SAB-176 & SAB-185 Designations & Announcements - 4 d SAb April 2023 BIOTHERAPEUTICS Granted Breakthrough Therapy Designation (BTD) and Fast Track designation by the FDA to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk pati

  3. Slide 3: Established Proof-of-Concept for SAB-176: Met Primary Endpoint in Phase 2a

    a Established Proof-of-Concept for SAB-176: Met Primary Endpoint of Viral Load Reduction in Phase 2a Challenge Study Achieved Statistically Significant ‘SAB-176 Achieved Statistically Significant SAB-176 Shortened Time of Viral Shedi (p = 0.026) Reduction in Viral Load — (p=0.013) Improvement in Sym

  4. Slide 4: SAB-185 Phase III: Time to All Targeted Symptoms Absent

    SAB-185 Phase III: Time (days) to All Targeted Symptoms Absent for 4 Consecutive Da Non-OMICRON Population OMICRON Population Tomar Toa 2003 SAB BIOTHERAPEUTICS. INC |OTHERAPEUTICS

  5. Slide 5: SAB-185: Key Symptom Data Recovery

    SAB-185: Key Symptom Data Recovery Table 5: Symptom Outcomes through Day 28 B Non-Omicron Population Omicron Population SAB-185 C+! Superiority p-value’ SAB-185 _C+l__—_‘Superiority p-value™ (N=142)__(N=153)_ Difference (95% CI> __(N=218)_(N=210)_Difference (95% Cl)® Symptom Improvement for at least

  6. Slide 6: SAB-142: Fully Human Anti-Thymocyte Globulin for Prevention of Type 1 Diabetes

    Yen BIOTHERAPEUTICS SAB-142: Fully Human Anti-Thymocyte Globulin for the Prevention of Type 1 Diabetes (T1D)

  7. Slide 7: SAB-142 has Strong Potential in Two Attractive T1D Markets

    SAB-142 has Strong Potential in Two Attractive TID Markets Stage 2 Prevention Market Tzield” — riectedto reach>s18 inww (teplizumab-mew) sales! by 2028 In the US, only family relatives are screened for T1D (<10% of patients), but screening programs are expanding $2.9B Sanofi acquisition of Proventio

  8. Slide 8: SAB-142: MoA Clinically Validated by 3rd Party Compound

    SAB-142: MoA Clinically Validated by 3" Party Compound 4 2 Years: Low-Dose ATG* Preserved C-Peptide in New Onset TID BIOTHERAPEUTICS HbA1c Over time by Treatment Group Placebo Se E ra p=0.011 ° ATG vsPlacebo rcabo i s: 3) Si fas « * o 3 6 8 ” ™ “RABBIT ATG FROM SANOFI - NOT SAB-142 (HUMAN TC-BOVINE

  9. Slide 9: Anti-Thymocyte Globulin (ATG) Demonstrates Strong Efficacy in T1D

    Anti-Thymocyte Globulin (ATG) Demonstrates Strong Hen Efficacy In TID ‘Anti-Thymocyte Globulin Polyclonal ab th 2015 2024 that restrai i henmuiespicn by Established T10 pilot study Recentonset T10 DRF x After 12 months C-peptide Ongoing MELD-ATG study to ing T-lymph targeting T-lymphocytes ‘was ~75%

  10. Slide 10: SAB-142 vs rATG and Teplizumab

    SAB-142 vs rATG and Teplizumab Projected favorable risk/benefit profile compared to other treatments Teplizumab (Tzield) |rATG Nature ofthe eee Multifactoriat: Bie eS0 Binds across ~40 markers Indications Stage2 (Q1 2023) Not approved 63% effect on C-peptide AUC after Efficacy con Immunogenicity: [J

  11. Slide 11: SAB-142 has an Identical MoA to rATG with Several Distinct Advantages

    SAB-142 has an Identical MoA to rATG with Several Wen, eas BIOTHERAPEUTICS Distinct Advantages Te Bovine Human-PB-ATG - SAB-142, Tiyfnoglobuin wh, Rabbit THYMO-AF488, and Equine ATGAM-AF488 Jayme eal bt BOMeRAPeUTICS r Majority of patients No serumsickness develop grade 3 @ expected due to fully ser

  12. Slide 12: Forward-Looking Statements

    Forward-Looking Statements 4 BIOTHERAPEUTICS Thematerial in this presentation hasbeen prepared by SAB Biotherapeutics, Inc. ("SAB") and is general background information about SAB’s activities, current as of the date ofthis presentation. Thisinformationis given in summary form and isnot intended to

  13. Slide 13: SAB-142: GLP Tox Study Results Enable IND Submission

    SAB-142: GLP Tox Study Results Enable IND Submission 4 Results: BIOTHERAPEUTICS GLP-tox study demonstrated SAB-142 is well tolerated at escalating doses tested Both SAB-142 and its active control, an FDA-approved rabbit-derived ATG, showed anticipated pharmacodynamic impact on the mature total lymph

  14. Slide 14: SAB-142: Clinical Development Plan T1D

    SAB-142: Clinical Development Plan T1D 2 4b PX SAb Phase1: Phase 2: Stable TID in adults ‘New Onset TID in Adults and Adolescents (Stage 3) Phase 1: Single Ascending Dose, open|abel design, SS=18 Phase 2: R, DB, PBO-controlleddesign in patients with New onset FA patients with stable T1D TAD (Stage 3

  15. Slide 15: SAB-142 Catalysts

    SAB-142 Catalysts Phase 1 First Phase 2 Phase 2 a Top-Line Readout Top-Line Phase 1 Study: Cohorts 1-4 Phase 1 Clinical Phase 1 Top Line Resuits SA Phase 2 Phase 2 Study POC/DRF © CTA Approved/CTN Acknowledged cmc Development (EEE FG to enable Phase 2 1= Fiat Point Pace Preafof Concept RF Dose-Ronge

  16. Slide 16: Selected Pipeline Programs

    Yew BIOTHERAPEUTICS SELECTED PIPELINE PROGRAMS

  17. Slide 17: SAB-176: First-In-Class Biologic Anti-Influenza Treatment

    Yen BIOTHERAPEUTICS SAB-176: (Expanded) First-In-Class Biologic Anti-Influenza Treatment (© 2023 SAB BIOTHERAPEUTICS, INC.

  18. Slide 18: Unmet Need of Seasonal Influenza

    Unmet Need of Seasonal Influenza 4, BIOTHERAPEUTICS Devastating health and economic impacts 35,500,000 + Estimated 30,000 - 50,000 deaths/year U.S. with 290,000 - 650,000 globally PMSEESSES + ~500,000 hospitalizations annually in U.S. 34,200 * Average US hospital stay: $8,000 - $9,000/day; 4-8 days/

  19. Slide 19: Value Proposition: SAB-176

    Value Proposition: SAB-176 26 2 PSA BIOTHERAPEUTICS First-in-class fully-human immunoglobulin treatment aimed to provide superior long-lasting efficacy for prophylaxis and management of influenza in high-risk patients Key Differentiators First and only broadly ‘Adaptive and cross- Multiprong neutral

  20. Slide 20: Only SAB-176 Provides Potential for "Evergreen" Influenza Biologic

    a Only SAB-176 Provides Potential for "EVERGREEN" Influenza Biologic with Low Risk of Escape Mutants First-in-class fully-human immunoglobulin treatment aimed to provide superior long- lasting efficacy for prophylaxis and management of influenza in patients at high-risk Broadly neutralizing Baloxavi

  21. Slide 21: Efficacy Against Mutational Drift

    Efficacy Against Mutational Drift: Oseltamivir Resistant (OR) HINIpdm Virus Challenge Model SAB-176 Showed 100% Protection at All Dose Levels From Mortality Huy BIOTHERAPEUTICS SAB-176 Protected Mice from Weight Loss While Oseltamivir Didn’t 100 Percent suv 0% survival in 100mg/kg/d Oseltamivir-trea

  22. Slide 22: SAB-185: SARS-CoV2 Infections

    Yen BIOTHERAPEUTICS SAB-185: (expanded) SARS-CoV2 Infections

  23. Slide 23: Investment Thesis

    Investment Thesis oie BIOTHERAPEUTICS > SAB Biotherapeutics is a next generation antibody platform company with human data in> 700 patients, recent receipt of Breakthrough Therapy and Fast Track designations, focused on Type 1 diabetes. > MoA of SAB-142 in T1D is a proven therapeutic approach with s

  24. Slide 24: SAB-185 Potential Value to Patients

    SAB-185 Potential Value to Patients as Only biologic with sustained efficacy across non-Omicron and Omicron variants in high-risk and low-risk patients Only antibody treatment designed to reduce risk of losing efficacy to escape mutants for high-risk COVID-19 patients Key Differentiators First-in-cl

  25. Slide 25: SARS-CoV2 Variants Associated with Ph2/3 ACTIV Trials

    SARS-CoV2 Variants Associated with Ph2/3 ACTIV Trials Omicron was a strain shift event and evolved during SAB-185 Ph3 enrollment a Pha Variants tone [omicronBa.a lomicronBa.2 lomicronBa.3 fl SAB-185 phe immunization Beta Strain Wu Han 2019 Gamma betta hambda Hasetne W.Bith Of Te Omicron Family BA1,

  26. Slide 26: SAB-195: Clostridioides difficile Infections

    Yen BIOTHERAPEUTICS SAB-195: Clostridioides difficile Infections (© 2025 SAB BIOTHERAPEUTICS, INC,

  27. Slide 27: High Unmet Medical Needs Remain

    High Unmet Medical Needs Remain 4 High Morbidity, Mortality, and Costs BIOTHERAPEUTICS Clostridioides difficile infection (CDI) is a bacterial infection of the large intestine (colon). A spectrum of clinical disease ranges from mild diarrhea to severe. CD1 is characterized by abdominal pain, fever,

  28. Slide 28: Value Proposition: SAB-195

    Er] Value Proposition: SAB-195 4, BIOTHERAPEUTICS First-in-class fully-human immunoglobulin treatment with dual mechanism of action designed to treat severe CDI and reduce CDI recurrence in high-risk patients Key Differentiators aiden eee First-in-class fully human Only treatment with dual ‘SAB-195

  29. Slide 29: Only SAB-195 Can Target Multiple C. diff Antigens and Toxins

    Only SAB-195 Can Target Multiple C. diff Antigens and Toxins in One Therapeutic First-in-class fully-human immunoglobulin treatment with dual mechanism of action designed to treat severe CDI and reduce CDI recurrence in high-risk patients Polyclonal Broadly Atbiotes | ntbodes | Meals (bezlotoxumab)

  30. Slide 30: SAB-195 Preclinical Data

    SAB-195 Preclinical Data 4 'SAb Tc bovine Immunized with Antigen Fusion Proteins Constructed BIOTHERAPEUTICS from Receptor Binding Domain of C. diff Toxin A (TcdA, C. diff Toxin B (TcdB)(630) and (TedB)(027) and Binary Toxin (CDT) B C. difficile strain 630 c C. difficile B1/NAP 1/027 001 1004 100: _

  31. Slide 31: Appendix

    Yen BIOTHERAPEUTICS APPENDIX (© 2025 SAB BIOTHERAPEUTICS, INC,

  32. Slide 32: Human Immunoglobulin G Produced in Transchromosomic Bovine

    Human Immunoglobulin G Produced in 2 38 Transchromosomic Bovine PX SAb BIOTHERAPEUTICS Tc Bovine” contain all the human immunoglobulin genes Tc Bovine™ * Only transgenic animal that carries the entire human immunoglobulin (Ig) heavy and light (x) chain loci + HAC is subject to mitosis along with the

  33. Slide 33: SAB Biotherapeutics Fact Sheet

    SAB Biotherapeutics Fact Sheet ON sab BIOTHERAPEUTICS 2 1 1 Yearsorlessfrom [J Anti-infective Percentsuccess [| Subjectstreated Assetsto date Only company to conceptto IND assets with rate from concept with SAB thatlostefficacy ff produce unlimited filing proven efficacy in toINDand therapeuticsin t

  34. Slide 34: Experienced Management Team

    Experienced Management Team 4 BIOTHERAPEUTICS ‘Samuel J. Reich Eddie J. Sullivan, PhD Russell Beyer, MBA, CMA EXECUTIVE CHAROUAN, B00 PRESIDENT 1 CEO /CO-FOUNDER EVP & CHEF FINANCIAL OFFICER oparme Executive and 800 20 years new technology ) 25 yeas Ph tune 100 ‘erelopment el egion CFO at, AstraZene

  35. Slide 35: Intellectual Property

    Intellectual Property 4 Regulatory Exclusivity Reference Product Exclusivity (RPE prevents censure of aBLA for biosilarSAB-176 {2040 + 6 mo PED!) LSE Reference Produc Exclusivity (RPE) prevents censure of aBLA for bosmilarSAB-CD1 (2041 + mo PED!) a Reference Product Exclusivity (PE) prevents censure

  36. Slide 36: DiversitAb Platform is Clinically Validated Across Several Targets

    DiversitAb™ Platform is Clinically Validated Across 4 Several Targets BO PeRAPEUTiCS Referenced Trials: Hled NUS and e-US O Safety, Tolerability, and Pharmacokinetics of SAB.176 in Healthy Participants - Full Text View -ClinicalTrals.gov Oi Study of $A8.176 inHealthy Adult Participants -Full Text Sp

  37. Slide 37: Scaled Infrastructure & Capacity: Tc Bovine & Plasma Production Facility

    Scaled Infrastructure & Capacity: Tc Bovine & Plasma Production Facility 4%... BIOTHERAPEUTICS

  38. Slide 38: Competitive Landscape (Immunosuppressive Agents)

    Competitive Landscape (Immunosuppressive Agents) Tzield Sronrnciy ae ec: eee ame Precii Phase 2 H Approved H Phase2 Phase 2 ‘Modality Human polyclonal Rabbit polyclonal + mAb i mAb mAb Impact on ¢- : ' = i re soar 103% | 183% | 38% i 37% Improvement in H ‘sTuDY i i HbaIc Mad | DEPENDENT =} tt) } ves

  39. Slide 39: Low-Dose rATG Provides the Greatest Relative Preservation of AUC C-peptide

    Low-Dose rATG Provides the Greatest Relative 2 Preservation of AUC C-peptide Ban, 7 7 BIOTHERAPEUTICS Low-dose ATG treatments both less costly and more effective relative to other immunotherapies and no treatment for new-onset Type 1 diabetes Percentage effect Percentage effect Tremont dose Cost, In

  40. Slide 40: Platform Technology

    Yen BIOTHERAPEUTICS Platform Technology (© 2025 SAB BIOTHERAPEUTICS, INC,

  41. Slide 41: Advancing a New Class of Immunotherapies with Initial Focus on T1D

    Advancing a New Class of Immunotherapies with Initial Focus on TID @ Robust, growing clinical-stage pipeline spanning multiple therapeutic areas IZA Vertical integration enables rapid, ag Leveraged advanced genetic engineering scalable & immune science development to develop of multi-targeted Tc bov

  42. Slide 42: SAB Human Immunoglobulin: Next Generation of Biologics

    SAB Human Immunoglobulin: Next Generation of Biologics Key Product Differentiators vs Monoclonal Antibodies: + Multi-target capability ina single therapeutic ¥ Natural multi-epitope targeted higG selected and produced in vivo ¥ Ability to target multiple disease pathways at once increase potential f

  43. Slide 43: SAB Platform has Broad Potential Therapeutic Applications

    SAB Platfi has Broad Potential Th tic Applicati atform has Broad Potential Therapeutic Applications Mens The Company is currently focusing its resources on the Type 1 Diabetes SAB-142 program; SAB is actively engaging in partnership for further development of other pipeline programs BIOTHERAREUTICS

  44. Slide 44: Positive Clinical Data in Flu and COVID

    are ates PXSAb : BIOTHERAPEUTICS Positive Clinical Data in Flu and COVID SAB-176: First-In-Class Biologic Anti-Influenza Treatment SAB-185: SARS-CoV2 Infections © 2023 SAB BIOTHERAPEUTICS, INC,

SAB Biotherapeutics — Investor Presentation (May 2023) on 6ix